Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Department of Surgery, Center for Neurobiology and Vaccine Development, Ophthalmology Research, Cedars-Sinai Burns and Allen Research Institute, Los Angeles, CA, USA.
J Exp Med. 2024 May 6;221(5). doi: 10.1084/jem.20231835. Epub 2024 Mar 26.
Mechanosensitive ion channels sense force and pressure in immune cells to drive the inflammatory response in highly mechanical organs. Here, we report that Piezo1 channels repress group 2 innate lymphoid cell (ILC2)-driven type 2 inflammation in the lungs. Piezo1 is induced on lung ILC2s upon activation, as genetic ablation of Piezo1 in ILC2s increases their function and exacerbates the development of airway hyperreactivity (AHR). Conversely, Piezo1 agonist Yoda1 reduces ILC2-driven lung inflammation. Mechanistically, Yoda1 inhibits ILC2 cytokine secretion and proliferation in a KLF2-dependent manner, as we found that Piezo1 engagement reduces ILC2 oxidative metabolism. Consequently, in vivo Yoda1 treatment reduces the development of AHR in experimental models of ILC2-driven allergic asthma. Human-circulating ILC2s express and induce Piezo1 upon activation, as Yoda1 treatment of humanized mice reduces human ILC2-driven AHR. Our studies define Piezo1 as a critical regulator of ILC2s, and we propose the potential of Piezo1 activation as a novel therapeutic approach for the treatment of ILC2-driven allergic asthma.
机械敏感离子通道感知免疫细胞中的力和压力,从而驱动高度机械性器官中的炎症反应。在这里,我们报告 Piezo1 通道抑制肺部 2 型固有淋巴细胞 (ILC2) 驱动的 2 型炎症。Piezo1 在肺 ILC2 激活时被诱导,因为 ILC2 中的 Piezo1 基因缺失会增加其功能并加剧气道高反应性 (AHR) 的发展。相反,Piezo1 激动剂 Yoda1 减少 ILC2 驱动的肺部炎症。从机制上讲,Yoda1 以 KLF2 依赖性方式抑制 ILC2 细胞因子的分泌和增殖,因为我们发现 Piezo1 结合会降低 ILC2 的氧化代谢。因此,体内 Yoda1 治疗可减少 ILC2 驱动的变应性哮喘实验模型中 AHR 的发展。循环中的人类 ILC2 在激活时表达并诱导 Piezo1,因为 Yoda1 处理人源化小鼠可减少人类 ILC2 驱动的 AHR。我们的研究将 Piezo1 定义为 ILC2 的关键调节因子,并提出激活 Piezo1 作为治疗 ILC2 驱动的变应性哮喘的新治疗方法的潜力。